PRODUCTIVITY LOSSES IN PHARMACOECONOMIC GUIDELINES IN EUROPE AND ASIA: A QUALITATIVE REVIEW OF GUIDELINES

被引：0
|
作者：
Nagano, M. [1 ]
Yuasa, A. [2 ]
Yonemoto, N. [3 ]
Ikeda, S. [4 ]
机构：
[1] Pfizer Japan Inc, Koto Ku, Tokyo 13, Japan
[2] Pfizer Japan Inc, Setagaya Ku, Tokyo 13, Japan
[3] Pfizer Japan Inc, Tokyo, Japan
[4] Int Univ Hlth & Welf, Narita, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA173
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [31] THE SOUTH AFRICAN GUIDELINES FOR PHARMACOECONOMIC SUBMISSIONS: A REVIEW IN CONTEXT OF EXISTING LEGISLATION AND CHALLENGES TO IMPLEMENTATION
    McGee, S.
    Truter, I
    Brand, M.
    La Cock, P.
    VALUE IN HEALTH, 2015, 18 (07) : A573 - A573
  • [32] Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening ProgrammesA Systematic Review on Content and Adherence to Guidelines
    Stefan Vegter
    Cornelis Boersma
    Mark Rozenbaum
    Bob Wilffert
    GerJan Navis
    Maarten J. Postma
    PharmacoEconomics, 2008, 26 : 569 - 587
  • [33] A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
    Basile, Michele
    Valentini, Ilaria
    Attanasio, Roberto
    Cozzi, Renato
    Persichetti, Agnese
    Samperi, Irene
    Scoppola, Alessandro
    Auriemma, Renata Simona
    De Menis, Ernesto
    Esposito, Felice
    Ferrante, Emanuele
    Iati, Giuseppe
    Mazzatenta, Diego
    Poggi, Maurizio
    Ruda, Roberta
    Tortora, Fabio
    Cruciani, Fabio
    Mitrova, Zuzana
    Saulle, Rosella
    Vecchi, Simona
    Cappabianca, Paolo
    Paoletta, Agostino
    Bozzao, Alessandro
    Caputo, Marco
    Doglietto, Francesco
    Ferrau, Francesco
    Lania, Andrea Gerardo
    Laureti, Stefano
    Lello, Stefano
    Locatelli, Davide
    Maffei, Pietro
    Minniti, Giuseppe
    Peri, Alessandro
    Ruini, Chiara
    Settanni, Fabio
    Silvani, Antonio
    Veronese, Nadia
    Grimaldi, Franco
    Papini, Enrico
    Cicchetti, Americo
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2024, 11 : 1 - 16
  • [34] PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIES
    Mihajlovic, J.
    Yegenoglu, S.
    Sahne, Sozen B.
    Postma, M.
    VALUE IN HEALTH, 2018, 21 : S194 - S194
  • [35] Japanese encephalitis: A review of clinical guidelines and vaccine availability in Asia
    Batchelor P.
    Petersen K.
    Tropical Diseases, Travel Medicine and Vaccines, 1 (1)
  • [36] Telemedicine Guidelines in South East Asia-A Scoping Review
    Sabrina, Mohamad Intan
    Defi, Irma Ruslina
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [37] A Review of Telemedicine Guidelines in the South-East Asia Region
    Sharma, Parth
    Sethi, Manik Inder Singh
    Liem, Andrian
    Bhatti, Hakikat Bir Singh
    Pandey, Vatsala
    Nair, Anoushka
    TELEMEDICINE REPORTS, 2023, 4 (01): : 271 - 278
  • [38] THE ROLE OF PHARMACOECONOMIC GUIDELINES FOR FORMULARY APPROVAL - THE AUSTRALIAN EXPERIENCE
    LANGLEY, PC
    CLINICAL THERAPEUTICS, 1993, 15 (06) : 1154 - 1176
  • [39] Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version
    Eun-Young Bae
    Jihyung Hong
    SeungJin Bae
    Seokyung Hahn
    Hyonggin An
    Eun-joo Hwang
    Seung-min Lee
    Tae-jin Lee
    Applied Health Economics and Health Policy, 2022, 20 : 467 - 477
  • [40] Providing systematic guidance in pharmacoeconomic guidelines for analysing costs
    Jacobs, P
    Ohinmaa, A
    Brady, B
    PHARMACOECONOMICS, 2005, 23 (02) : 143 - 153
12345